Opinion: Don't expect much soon: Mentor

[Guest guest]

Well I hope that motley fool is right. http://www.fool.com/news/mft/2006/mft06020920.htm?source=eptyholnk303100 & logvisit=y & npu=y & bounce=y & bounce2=y Investors hoping that Mentor would be kicking up its growth any time soon found themselves doused with some cold water. The company is still in discussions with the Food and Drug Administration on the approval of a silicone breast implant, and it's anybody's guess as to when this finally gets ironed out. The FDA is understandably worried about the safety ramifications of this product, and the company needs to offer up a credible approach for post-approval safety monitoring and tracking. It's just one Fool's guess, but I wouldn't expect much to happen in the near term. In other news,

the company seems to be having data problems with a study of its Puragen Plus dermal filler, and that's going to indefinitely delay a filing with the FDA. What's more, management has dropped its pursuit of Medicis (NYSE: MRX), since, although this acquisition would have been good for Mentor, the Medicis board didn't seem too accommodating. Assuming that the company can sell its urology business (and management seems optimistic there), Mentor will probably look for more acquisitions to grow the aesthetics business. It certainly needs to do something; just standing in place is not going to build much shareholder value, and I don't think the introduction of silicone breast implants is going to be a transformative act. If management can

close the right deals, maybe this company will snap-to and get a little more interesting again.

Bring photos to life! New PhotoMail makes sharing a breeze.

[Guest guest]

I wonder if Motley fool has been reading 's

financial page on Mentor! . . . If so, they know

Mentor has a huge problem!

I hope everyone takes a look a it!

Hugs,

Rogene

--- Tricia Trish <glory2glory1401@...> wrote:

> Well I hope that motley fool is right.

>

>

>

http://www.fool.com/news/mft/2006/mft06020920.htm?source=eptyholnk303100 & logvisi\

t=y & npu=y & bounce=y & bounce2=y

> Investors hoping that Mentor would be kicking up

> its growth any time soon found themselves doused

> with some cold water. The company is still in

> discussions with the Food and Drug Administration on

> the approval of a silicone breast implant, and it's

> anybody's guess as to when this finally gets ironed

> out. The FDA is understandably worried about the

> safety ramifications of this product, and the

> company needs to offer up a credible approach for

> post-approval safety monitoring and tracking. It's

> just one Fool's guess, but I wouldn't expect much to

> happen in the near term.

>

> In other news, the company seems to be having data

> problems with a study of its Puragen Plus dermal

> filler, and that's going to indefinitely delay a

> filing with the FDA. What's more, management has

> dropped its pursuit of Medicis (NYSE: MRX), since,

> although this acquisition would have been good for

> Mentor, the Medicis board didn't seem too

> accommodating.

>

> Assuming that the company can sell its urology

> business (and management seems optimistic there),

> Mentor will probably look for more acquisitions to

> grow the aesthetics business. It certainly needs to

> do something; just standing in place is not going to

> build much shareholder value, and I don't think the

> introduction of silicone breast implants is going to

> be a transformative act. If management can close the

> right deals, maybe this company will snap-to and get

> a little more interesting again.

>

>

> ---------------------------------

>

> Bring photos to life! New PhotoMail makes sharing a

> breeze.